rs562882648

Variant summary

Our verdict is Benign. The variant received -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2

The NM_001134363.3(RBM20):​c.2547T>A​(p.Asn849Lys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000283 in 1,448,140 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. N849H) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.00018 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000011 ( 0 hom. )

Consequence

RBM20
NM_001134363.3 missense

Scores

2
14

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:3B:1

Conservation

PhyloP100: 0.404

Publications

0 publications found
Variant links:
Genes affected
RBM20 (HGNC:27424): (RNA binding motif protein 20) This gene encodes a protein that binds RNA and regulates splicing. Mutations in this gene have been associated with familial dilated cardiomyopathy. [provided by RefSeq, Apr 2014]
RBM20 Gene-Disease associations (from GenCC):
  • dilated cardiomyopathy
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • dilated cardiomyopathy 1DD
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
  • familial isolated dilated cardiomyopathy
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • hypertrophic cardiomyopathy
    Inheritance: AD Classification: LIMITED Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -13 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.06480649).
BP6
Variant 10-110812944-T-A is Benign according to our data. Variant chr10-110812944-T-A is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 202048.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.000177 (27/152142) while in subpopulation AFR AF = 0.000651 (27/41498). AF 95% confidence interval is 0.000459. There are 0 homozygotes in GnomAd4. There are 11 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High AC in GnomAd4 at 27 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
RBM20NM_001134363.3 linkc.2547T>A p.Asn849Lys missense_variant Exon 9 of 14 ENST00000369519.4 NP_001127835.2 Q5T481
RBM20XM_017016103.3 linkc.2382T>A p.Asn794Lys missense_variant Exon 9 of 14 XP_016871592.1
RBM20XM_017016104.3 linkc.2163T>A p.Asn721Lys missense_variant Exon 9 of 14 XP_016871593.1
RBM20XM_047425116.1 linkc.2163T>A p.Asn721Lys missense_variant Exon 9 of 14 XP_047281072.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
RBM20ENST00000369519.4 linkc.2547T>A p.Asn849Lys missense_variant Exon 9 of 14 1 NM_001134363.3 ENSP00000358532.3 Q5T481
RBM20ENST00000718239.1 linkc.2547T>A p.Asn849Lys missense_variant Exon 9 of 14 ENSP00000520684.1

Frequencies

GnomAD3 genomes
AF:
0.000171
AC:
26
AN:
152024
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000628
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.0000497
AC:
4
AN:
80464
AF XY:
0.0000255
show subpopulations
Gnomad AFR exome
AF:
0.000438
Gnomad AMR exome
AF:
0.0000960
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000108
AC:
14
AN:
1295998
Hom.:
0
Cov.:
30
AF XY:
0.00000957
AC XY:
6
AN XY:
627182
show subpopulations
African (AFR)
AF:
0.000425
AC:
12
AN:
28256
American (AMR)
AF:
0.0000516
AC:
1
AN:
19386
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
18894
East Asian (EAS)
AF:
0.00
AC:
0
AN:
34760
South Asian (SAS)
AF:
0.00
AC:
0
AN:
60576
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
45064
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5218
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
1030292
Other (OTH)
AF:
0.0000187
AC:
1
AN:
53552
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.496
Heterozygous variant carriers
0
1
2
4
5
6
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000177
AC:
27
AN:
152142
Hom.:
0
Cov.:
32
AF XY:
0.000148
AC XY:
11
AN XY:
74380
show subpopulations
African (AFR)
AF:
0.000651
AC:
27
AN:
41498
American (AMR)
AF:
0.00
AC:
0
AN:
15296
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5170
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4814
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10584
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
67990
Other (OTH)
AF:
0.00
AC:
0
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.525
Heterozygous variant carriers
0
2
4
6
8
10
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000214
Hom.:
0
Bravo
AF:
0.000196

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:3Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not specified Uncertain:1
Aug 07, 2022
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: RBM20 c.2547T>A (p.Asn849Lys) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 5e-05 in 80464 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.2547T>A has been reported in at-least one individual from the Percutaneous Stem Cell Injection Delivery Effects On Neomyogenesisin Dilated Cardiomyopathy trial (POSEIDON-DCM; NCT01392625) and authors classified the variant as VUS (Rieger_2019). This report does not provide unequivocal conclusions about association of the variant with Dilated Cardiomyopathy. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014and classified the variant as likely benign, and as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. -

not provided Uncertain:1
Feb 11, 2025
GeneDx
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 31648988) -

Cardiovascular phenotype Uncertain:1
Oct 08, 2024
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.N849K variant (also known as c.2547T>A), located in coding exon 9 of the RBM20 gene, results from a T to A substitution at nucleotide position 2547. The asparagine at codon 849 is replaced by lysine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -

Dilated cardiomyopathy 1DD Benign:1
Jan 23, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.13
BayesDel_addAF
Benign
-0.32
T
BayesDel_noAF
Benign
-0.35
CADD
Benign
15
DANN
Uncertain
0.99
Eigen
Benign
-0.14
Eigen_PC
Benign
-0.080
FATHMM_MKL
Benign
0.75
D
M_CAP
Benign
0.039
D
MetaRNN
Benign
0.065
T
MetaSVM
Benign
-0.74
T
PhyloP100
0.40
PrimateAI
Benign
0.37
T
PROVEAN
Benign
-1.1
N
REVEL
Benign
0.088
Sift
Uncertain
0.0020
D
Sift4G
Benign
0.39
T
Vest4
0.26
MutPred
0.25
Gain of ubiquitination at N849 (P = 0.0045);
MVP
0.47
ClinPred
0.084
T
GERP RS
1.6
gMVP
0.052
Mutation Taster
=88/12
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.060
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs562882648; hg19: chr10-112572702; API